Can Clindamycin treat UTI?
By
Dr Milena Locci de Oliveira (PhD)
Author bio
Dr Milena Locci de Oliveira is a Pharmacist and Doctor of Philosophy in Sciences from the University of São Paulo (USP). She has experience in microbiology, analytical toxicology, and clinical pharmacokinetics. She writes and reviews content on these topics.
Dr Milena’s Highlights:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration in the areas of Pharmacometrics and Population Pharmacokinetics, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
“Science can be translated, and it is essential that everyone has access to quality information to make informed decisions” – Dr Milena Oliveira, PhD.
Professional Experience:
With a decade-long career as a researcher, Dr Milena has amassed extensive experience in conducting research projects in microbiology, analytical toxicology, and clinical pharmacokinetics.
Her expertise also extends to the preparation of technical and scientific reports, literature reviews, data analysis, and scientific communication, both oral and written.
Dr Milena has served as a Clinical Pharmacist, providing expert supervision and guidance to teams during the challenging times of the COVID-19 pandemic, particularly in the ICUs of two reference hospitals for patient hospitalization.
In her most recent role, Dr Milena worked on the implementation of the deliberatives of the São Paulo State Government Pharmaceutical Assistance Coordination. These decisions were aimed at ensuring medication access within the Unified Health System.
A widely multidisciplinary background enabled Dr Milena to become a professional capable of integrating scientific knowledge into private initiatives, education, and healthcare, delivering consistent services in patient safety and population health.
Professional Memberships & Affiliations:
Dr Milena Oliveira is a member of the Regional Council of Pharmacy of the State of São Paulo, Brazil.
Education:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
Relevant Published Work & Citations:
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis. Nov 2020. 191:113-124.
Abstracts. CPT: Pharmacometrics & Systems Pharmacology. 2020 Nov; 9 (S1).
Pippa LF, Oliveira ML de, Rocha A, de Andrade JM, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis. 2020 Jun 5; 185:113-231.
Godoy ALPC, De Jesus C, De Oliveira ML, Rocha A, Pereira MPM, Larangeira DF, Lanchote VL, Barrouin-Melo SM. Determination of Allopurinol and Oxypurinol in Dogs Plasma by High-Performance Liquid Chromatography with an Ultraviolet Detector: Application for Pharmacokinetic Studies. J Chromatogr Sep Tech. 2017; 8 (4).
Clímaco EC, Oliveira ML de, Pitondo-Silva A, Oliveira MG, Medeiros M, Lincopan N, et al. Clonal complexes 104, 109 and 113 playing a major role in the dissemination of OXA-carbapenemase-producing Acinetobacter baumannii in Southeast Brazil. Infection, Genetics and Evolution. 2013 Oct;19:127–33.
Conference Papers:
Oliveira, M. L.; NARDOTTO, G. H. B.; PIPPA, L. F.; ROCHA, A.; SIMOES, B. P.; LANCHOTE, V. L. . Daunorubicin metabolism and urinary excretion in patients with acute myeloid leukemia. In: 84th Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) and the 20th Annual Meeting of the Association of the Clinical Pharmacology Germany (VKliPha), 2018, Göttingen. Naunyn-Schmiedeberg’s Arch Pharmacol, 2018. v. 391. p. S76-S76.
Oliveira, M. L.; NARDOTTO, G. H. B. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . The low contribution of urinary excretion in the elimination of daunorubicin and its metabolite daunorubicinol in patients with acute myeloid leukemia. In: 49th Brazilian Congress of Pharmacology and Experimental Therapeutics., 2017, Ribeirão Preto. Livro de Resumos, 2017. p. 64-64.
Oliveira, M. L.; PIPPA, L. F. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . Quantification of daunorubicin and its metabolite daunorubicinol in human plasma by LC-MS/MS. In: I International Meeting of Environmental Health and Toxicology (IMEHTOX), 2016, Ribeirão Preto. Livro de Resumos, 2016.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. . PFGE typing of Carbapenem-Resistant Acinetobacter baumannii isolated from different University Hospitals. In: V International Postgraduate and Research Symposium, 2012.
Clímaco, E.C. ; SILVA, A. P. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. Relação clonal entre linhagens de Acinetobacter baumannii produtoras de carbapenemases da família OXA em quatro hospitais no Brasil. In: XXI Latin American Congress of Microbiology, 2012, Santos. XXI Latin American Congress of Microbiology, 2012.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Darini A.L.C. . Dissemintion of OXA carbapenemases genes in carbapenem-resistant Acinetobacter baumannii in University Hospital of Juiz de Fora, MG. In: 8th CIFARP – International Congress of Pharmaceutical Sciences, 2011, Ribeirão Preto.
Clímaco, E.C. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Darini A.L.C. . Avaliação do sequenciamento parcial do gene rpoB e de seus flanqueadores para identificação de espécies de Acinetobacter na rotina laroratorial. In: 2° International Symposium on Clinical Microbiology, 2010, Florianópolis.
You can view some of Dr Milena’s work below and links to her professional profile.
Linkedin: https://www.linkedin.com/in/dra-milena-locci-de-oliveira-28986042/?locale=en_US
ResearchGate: https://www.researchgate.net/profile/Milena-Oliveira-6
Escavador: https://www.escavador.com/sobre/5394254/milena-locci-de-oliveira
Lattes: https://buscatextual.cnpq.br/buscatextual/busca.do
Scopus: https://www.scopus.com/authid/detail.uri?authorId=57199779361
Scholar: https://scholar.google.com/citations?view_op=list_works&hl=pt-BR&user=1YUBDIQAAAAJ
Can Clindamycin treat UTI?
Clindamycin may help your UTI, but it is not generally considered strong enough to completely cure urinary tract infections. Clindamycin is considered more active against infections of the skin, ear, lungs, blood, and the female reproductive system, but it is not known for treating UTIs.
If you think you have a UTI, talk to your healthcare provider. Urine tract infections should not be neglected and must be diagnosed properly.
What medications treat UTI?
There are a number of antibiotics which are used to treat complicated and uncomplicated UTIs. Some of the common ones include (1):
- Cephalosporins, like Ceftriaxone, Cephalexin, etc.
- Fluoroquinolones, like Ciprofloxacin
- Trimethoprim and Sulfamethoxazole
- Nitrofurantoin
- Fosfomycin
The antibiotic of choice for you not only depends on the basic facts but also on your overall health status. Let’s say you’re allergic to Cephalosporins, your doctor won’t prescribe you one no matter how effectively the med can treat UTI.
It’s just not an option for you. That’s when your doctor will prescribe you the next best thing to manage your symptoms effectively. This is why it’s never the right choice to start taking antibiotics on your own.
Just talk to your doctor and get a proper prescription. There are other things that may also help your UTI, like drinking cranberry juice and lots of fluids in general (2).
Probiotics can also be used for the management of UTIs (3). However, these add-ons will not likely be sufficient enough to kill the infection-causing bacteria since only an antibiotic can achieve that goal.
Furthermore, OTC non-steroidal anti-inflammatory drugs can also be used for the management of pain and inflammation associated with UTI. Some examples include Naproxen, Ibuprofen, etc. However, some NSAIDs are not commonly used for this purpose, such as Meloxicam, Indomethacin, etc.
So, make sure you talk to your doctor or pharmacist to make sure that you are taking the right painkiller to help manage flank pain associated with UTIs.
How to know you have a urinary tract infection?
UTIs are commonly associated with the following signs and symptoms:
- Pain or burning sensation during urination
- Frequent urge to urinate, even when little comes out
- Cloudy or strong-smelling urine
- Blood in the urine
- Lower abdominal pain or pressure
- Fever or chills
- Nausea or vomiting
It is important to visit your health giver and get a proper diagnosis. If you have a UTI, it should never go untreated. If a UTI spreads to the kidneys, it can cause a more serious infection known as pyelonephritis.
This can lead to high fever, chills, nausea, vomiting, and back pain. If left untreated, pyelonephritis can cause permanent kidney damage or sepsis, a potentially life-threatening condition.
If bacteria from an untreated UTI enter the bloodstream, they can cause a potentially fatal condition that occurs when the body’s immune system overreacts to an infection – called Sepsis.
Symptoms of sepsis include fever, low blood pressure, rapid heart rate, confusion, and difficulty breathing. This is why seeking medical attention is crucial.
Was this helpful?
References
1.-
National Health Services. Urinary tract infections (UTIs) – NHS [Internet]. National Health Service (NHS). [Accessed 23 Jan 2023]. Available from: https://www.nhs.uk/conditions/urinary-tract-infections-utis/.
2.-
Hisano M, Bruschini H, Nicodemo AC, Srougi M. Cranberries and lower urinary tract infection prevention. Clinics (Sao Paulo). 2012;67(6):661-8. doi: 10.6061/clinics/2012(06)18. PMID: 22760907; PMCID: PMC3370320. Available from: https://pubmed.ncbi.nlm.nih.gov/22760907/
3.-
Falagas ME, Betsi GI, Tokas T, Athanasiou S. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs. 2006;66(9):1253-61. doi: 10.2165/00003495-200666090-00007. PMID: 16827601. Available from: https://pubmed.ncbi.nlm.nih.gov/16827601/
